Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Epilepsy Market Report 2018-2027 - Drivers and Barriers - The US Accounted for Most Cases in 2016 Followed by Germany -

Research and Markets
Posted on: 22 Feb 18

The "Epilepsy - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Epilepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Epilepsy market is expected to grow during the forecasted period of 2018-2027 owing to the launch of nine drugs (presently in Phase III). Epilepsy Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.

According to research, the prevalent cases of Epilepsy was 7,649,695 in 2016 in 7MM. Among 7MM, United States account for highest prevalent cases of Epilepsy with 4,007,026 prevalent cases in 2016 followed by Germany.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Epilepsy from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Companies Mentioned

  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • Marinus Pharmaceuticals
  • Pfizer
  • Sage Therapeutics
  • UCB
  • Ultragenyx Pharmaceutical
  • Zogenix
  • Zynerba Pharma

Key Topics Covered:

1. Report Summary

2. Epilepsy Disease Background

3. Epidemiology and Patient Population

4. Treatment Algorithm

5. Unmet Needs

6. Competitive Landscape - Marketed Drugs

7. Emerging Therapies

8. Market Size of Epilepsy

9. Global Market Size

10. United States

11. EU5

12. Japan

13. Market Drivers

14. Market Barriers

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 22/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.